Ann: FDA approval to supply infant milk formula to United States, page-45

They provided following information in their last report just a month ago:
• Pokeno’s multinational customer
• Product trials are progressing and construction is inthe final stage of commissioning. There have been nochanges to previously communicated CAPEX spend orvolume expectations across the contract term.
• Commercial production starts in early 2023, with productplanned for distribution in Southeast Asia from Q2 2023.Distribution markets have expanded to include Australiaand New Zealand by the end of 2023 (calendar year).
• Additional product trials are commencing towards theend of the 2022 calendar year for new products in theclinical nutrition category.
• An investor Day will be held at Synlait Pokeno in May2023 (further details on page 28).

As for your other questions. Gross margin is always lower at the beginning when establishing new line of products as they usually have higher cost of goods expenses associated with it. Company stated they would need new scoops, instructions, labeling and obviously adjust production line and some other expenses.

At better days, by my estimations, they produced around 40m tins year. If current production is 30m I do not see much problems for them to add extra 9m at this stage.
Not sure I understand your remark about Pokeno.